Curiosis
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
Curiosis makes laboratory automation equipment, instruments that let scientists observe living cells growing inside incubators and separate specific cells or blood components without manual handling.
Its products are used in life-science research, drug development, diagnostics, and the production of cell-based therapies. Listed on KOSDAQ, Korea's tech-focused small-cap board, the company designs and manufactures its products in-house, with its live-cell imaging system, the Celloger® series, serving as its primary revenue-driving product line.
Summary is AI-generated and may contain errors · figures from DART filings
Curiosis has received recognition from Korea's Ministry of Trade, Industry and Energy, which designated the Celloger® as a 'World Class Product', a formal Korean government certification for globally competitive exports.
Curiosis in five facts
What does Curiosis do?
Curiosis makes laboratory automation equipment, instruments that let scientists observe living cells growing inside incubators and separate specific cells or blood components without manual handling.
Where is Curiosis listed and in which sector?
Curiosis (Korean name: 큐리오시스) trades under KRX code 494120 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Information Technology sector, Components.
How large is Curiosis?
Its market capitalisation was US$93.5M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were Curiosis's latest annual revenue and operating profit?
For fiscal year 2025, Curiosis reported revenue of US$5.5M, an operating loss of US$5.7M and a net loss of US$5.9M, per its annual report on DART (data retrieved from DART on 2026-06-04).
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-06-04
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Investor relations (IR) meetingOct 6
- Report on securities held by executives/major shareholdersSep 4
- Ex-rights (bonus issue)
Curiosis common shares (code A494120) will trade ex-rights from July 15, 2026 at a base price of US$8.59 in connection with a bonus share issue.
Capital raise · Jul 14 - Trading suspension (bonus issue)Capital raise · Jun 29
- Material event report (bonus issue)Capital raise · Jun 29
- [Amended] Supply contract signed
Curiosis updated a previously disclosed supply contract, now worth US$1.42M, about 44.36% of its recent annual revenue, running through Apr 2026.
Supply contract · Mar 5 - Material management matter relevant to investment decisionsSupply contract · Jan 23
- Change of 30% or more in revenue or profit/loss structure (15% for large companies)Earnings · Jan 21